To delineate mutational landscape of patients with myelofibrosis. Next-generation sequencing for patients with myelofibrosis

With the advent of next-generation sequencing (NGS) and its wide application in mutation detection in myeloid malignancies, high-risk gene mutations were incorporated in novel prognostic models, including Mutation-Enhanced IPSS 70 (MIPSS70), MIPSS70 plus version 2.0, and Genetically Inspired Prognostic Scoring System (GIPSS). These novel prognostic models applied not only traditional clinical parameters and cytogenetics, but also mutation statuses, underscoring the independent prognostic contribution of the driver and high molecular risk mutations.